Regulation of bone remodeling and disease. Glucocorticoid-induced abnormality in bone remodeling. Tanaka Yoshiya 1 1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan. pp.1731-1738
Published Date 2017/11/28
DOI https://doi.org/10.20837/4201712057
  • Abstract
  • Look Inside
  • Reference

 Glucocorticoid(GC)is widely used to treat a variety of autoimmune, inflammatory and allergic diseases. GC causes a number of adverse effects and among them osteoporosis and degenerative bone fracture are major complications of GC therapy. GC inhibits differentiation of mesenchymal stem cells to osteoblasts, induces apoptosis of osteoblasts and osteocytes and prolongs lifespan of osteoclast, resulting in low bone mass and micro-architectural deterioration of bone tissue, which leads to severe osteoporosis, increased bone fragility and susceptibility to bone fracture. Physicians who prescribe GC have to manage patients according to guidelines on the management and treatment of GC-induced osteoporosis.


電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社